Ahmed Jaboob, Abdullah Al Asmi, M Mazharul Islam, Syed Rezvi, Iman Redha, Jaber Al-Khabouri, Ibrahim Al-Zakwani, Ahmed Al-Qassabi, Haifa Al-Abri, Arunodaya R Gujjar
OBJECTIVES: Dimethyl fumarate (DMF) is known to cause lymphopenia when used to treat patients with multiple sclerosis (MS). However, research on DMF therapy in the Arab world, especially in Oman, is scarce. This study aimed to analyse the prevalence of lymphopenia among Omani patients with MS and their reasons for discontinuing DMF therapy. METHODS: In this retrospective study, the medical records of Omani patients with MS who were treated using DMF at two tertiary hospitals in Muscat, Oman, from February 2017 to February 2023 were reviewed...
February 2024: Sultan Qaboos University Medical Journal